
SGHT
Sight Sciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.450
Open
3.450
VWAP
3.45
Vol
941.00
Mkt Cap
178.37M
Low
3.450
Amount
3.25K
EV/EBITDA(TTM)
--
Total Shares
49.76M
EV
109.19M
EV/OCF(TTM)
--
P/S(TTM)
2.23
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
19.02M
-0.29%
-0.284
+23.4%
17.53M
-13.02%
-0.288
+30.85%
18.18M
-14.92%
-0.272
+8.81%
Estimates Revision
The market is revising Upward the revenue expectations for Sight Sciences, Inc. (SGHT) for FY2025, with the revenue forecasts being adjusted by 2.14% over the past three months. During the same period, the stock price has changed by 12.01%.
Revenue Estimates for FY2025
Revise Upward

+2.14%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+3.9%
In Past 3 Month
Stock Price
Go Up

+12.01%
In Past 3 Month
7 Analyst Rating

7.83% Upside
Wall Street analysts forecast SGHT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is 3.72 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
6 Hold
0 Sell
Hold

7.83% Upside
Current: 3.450

Low
3.00
Averages
3.72
High
4.00

7.83% Upside
Current: 3.450

Low
3.00
Averages
3.72
High
4.00
Morgan Stanley
Equal Weight
maintain
$3 -> $4
2025-07-15
Reason
Morgan Stanley
Price Target
$3 -> $4
2025-07-15
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Sight Sciences to $4 from $3 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Piper Sandler
Matt O'Brien
Neutral
maintain
$4
2025-06-19
Reason
Piper Sandler
Matt O'Brien
Price Target
$4
2025-06-19
maintain
Neutral
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Sight Sciences to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes shares of Sight Sciences have seen some recovery year-to-date, up +10.7% after a challenging 2024 campaign. Piper likes the company's MIGS technology and views the company's dry eye asset as an intriguing product in a large end-market, but it wrestles with uncertainty in the glaucoma business, namely the late '24 LCD reimbursement change and potential trialing of a recent competitor product launch. Further, Piper suspects Sight Sciences will need to access the capital markets in the next 1-2 years, and it thinks it will take dry eye at least several quarters to find its stride with the change in commercial/reimbursement strategy.
Citi
Neutral
maintain
2025-05-22
Reason
Citi
Price Target
2025-05-22
maintain
Neutral
Reason
Citi raised the firm's price target on Sight Sciences to $3.60 from $3.20 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Lake Street
Hold
maintain
$3
2025-05-09
Reason
Lake Street
Price Target
$3
2025-05-09
maintain
Hold
Reason
Lake Street raised the firm's price target on Sight Sciences to $3 from $2.50 and keeps a Hold rating on the shares. The firm, which believes Q1 highlights stabilization in the face of MIGS LCD pressures, continues to see potential for reacceleration in 2026 and thinks shares are likely trading near a trough multiple, but also believes broader payer progress on TearCare and normalized MIGS procedure volumes will be required to support growth acceleration.
Needham
David Saxon
Hold
Reiterates
n/a
2025-04-09
Reason
Needham
David Saxon
Price Target
n/a
2025-04-09
Reiterates
Hold
Reason
Needham
David Saxon
Hold
Reiterates
n/a
2025-03-06
Reason
Needham
David Saxon
Price Target
n/a
2025-03-06
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sight Sciences Inc (SGHT.O) is -3.24, compared to its 5-year average forward P/E of -7.32. For a more detailed relative valuation and DCF analysis to assess Sight Sciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-7.32
Current PE
-3.24
Overvalued PE
-2.70
Undervalued PE
-11.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-6.21
Current EV/EBITDA
-2.79
Overvalued EV/EBITDA
0.62
Undervalued EV/EBITDA
-13.04
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
6.16
Current PS
2.47
Overvalued PS
12.13
Undervalued PS
0.18
Financials
Annual
Quarterly
FY2025Q1
YoY :
-9.12%
17.51M
Total Revenue
FY2025Q1
YoY :
-5.87%
-13.86M
Operating Profit
FY2025Q1
YoY :
-12.98%
-14.15M
Net Income after Tax
FY2025Q1
YoY :
-15.15%
-0.28
EPS - Diluted
FY2025Q1
YoY :
+17.19%
-11.61M
Free Cash Flow
FY2025Q1
YoY :
+0.83%
86.21
Gross Profit Margin - %
FY2025Q1
YoY :
-36.83%
-31.29
FCF Margin - %
FY2025Q1
YoY :
-4.25%
-80.84
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
304.5K
USD
6
3-6
Months
147.6K
USD
5
6-9
Months
233.0K
USD
9
0-12
Months
2.8M
USD
10
Bought
0-3
9
1.2M
USD
Months
3-6
2
53.3K
USD
Months
6-9
2
32.4K
USD
Months
0-12
3
2.1M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
887.9K
Volume
Months
6-9
1
1.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
304.5K
USD
6
3-6
Months
147.6K
USD
5
6-9
Months
233.0K
USD
9
0-12
Months
2.8M
USD
10
Bought
0-3
9
1.2M
USD
Months
3-6
2
53.3K
USD
Months
6-9
2
32.4K
USD
Months
0-12
3
2.1M
USD
Months
SGHT News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
07:17:32
Sight Sciences announces results of CUA assessing TearCare system

2025-07-29 (ET)
2025-07-29
07:09:41
Sight Sciences announces publication of 24-month results of SAHARA RCT

2025-05-08 (ET)
2025-05-08
16:50:35
Sight Sciences has exposure to tariffs imposed by the U.S. on China

Sign Up For More Events
Sign Up For More Events
News
9.0
07-29NewsfilterPinnedSight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
5.0
07-08NASDAQ.COMInsider Sale: Chief Financial Officer of $SGHT Sells 19,260 Shares
4.0
06-18BenzingaPiper Sandler Maintains Neutral on Sight Sciences, Raises Price Target to $4
Sign Up For More News
People Also Watch

OPRT
Oportun Financial Corp
6.170
USD
-0.16%

VTYX
Ventyx Biosciences Inc
2.690
USD
0.00%

VERU
Veru Inc
0.493
USD
0.00%

WHG
Westwood Holdings Group Inc
17.610
USD
0.00%

FRGE
Forge Global Holdings Inc
16.910
USD
+0.54%

ALTO
Alto Ingredients Inc
1.040
USD
0.00%

TDTH
Trident Digital Tech Holdings Ltd
1.400
USD
0.00%

INMB
INmune Bio Inc
2.700
USD
+0.75%

MPAA
Motorcar Parts of America Inc
10.700
USD
0.00%

HOFT
Hooker Furnishings Corp
9.800
USD
0.00%
FAQ

What is Sight Sciences Inc (SGHT) stock price today?
The current price of SGHT is 3.45 USD — it has increased 0 % in the last trading day.

What is Sight Sciences Inc (SGHT)'s business?

What is the price predicton of SGHT Stock?

What is Sight Sciences Inc (SGHT)'s revenue for the last quarter?

What is Sight Sciences Inc (SGHT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Sight Sciences Inc (SGHT)'s fundamentals?

How many employees does Sight Sciences Inc (SGHT). have?
